tanning peptides FAQ

Transition protocols for switching from broad-spectrum MT-II to MC1R-selective analogs require dose adjustment because receptor selectivity changes effective melanogenesis potency. Afamelanotide derivatives typically require 40–60% lower dosing than MT-II to achieve equivalent melanin induction due to reduced receptor competition from MC3R and MC4R binding. Start with conservative dosing (0.25–0.5mg for afamelanotide derivatives vs 0.5–1.0mg typical MT-II doses) and titrate based on melanogenesis response, which becomes visible 7–10 days post-administration as eumelanin accumulates in the epidermis. The primary advantage of MC1R-selective compounds is not faster pigmentation but reduced nausea and facial flushing. Expect similar melanogenesis timelines with fewer systemic side effects.

Discard any melanotan II vials without accompanying certificates of analysis showing batch-specific sterility testing. The recalled batches lacked sterility verification, meaning bacterial contamination cannot be ruled out visually or through at-home testing. If your supplier provided a CoA with the original shipment showing HPLC purity and LAL endotoxin results, cross-reference the batch number against the FDA's March 2026 recall list (publicly available through the FDA's Recalls, Market Withdrawals & Safety Alerts database). Vials from non-recalled batches with verified sterility remain usable within their labeled expiration dates, but reconstituted solutions should still be used within 28 days when stored at 2–8°C.

Many peptide suppliers removed public melanotan listings in 2026 to avoid state-level cosmetic peptide enforcement while continuing to supply registered researchers through request-based systems. Contact your supplier directly and request information on melanocortin peptides for MC1R receptor research. Phrasing the inquiry as a research application rather than a tanning application signals compliance with current marketing restrictions. If your supplier cannot provide CoAs showing third-party HPLC verification and sterility testing, source from an alternative supplier that operates under FDA-registered 503B standards. Real Peptides maintains documentation for all melanocortin peptides specifically because the request-based model requires transparent verification that peptides meet cGMP synthesis standards.

Assume complete degradation if the peptide was reconstituted. Lyophilised powder can tolerate short-term ambient exposure (up to 25°C for 24–48 hours), but once mixed with bacteriostatic water, protein denaturation begins above 8°C. There's no home test for potency loss. The solution may look clear and unchanged, but the peptide structure is compromised. Dispose of the vial and source a replacement. For travel, use a medical-grade cooler like FRIO wallets that maintain 2–8°C without electricity for 36–48 hours.

Nausea from melanotan II has two causes: MC3R/MC4R receptor activation (mechanism-driven) and peptide impurities (contaminant-driven). If nausea appears within 30–60 minutes of injection and resolves within 4–6 hours, it's receptor-mediated. Reduce dose by 50% and titrate more slowly. If nausea persists beyond 8 hours or worsens with each injection, suspect peptide impurity. Request a replacement batch with an HPLC certificate above 98% purity. Persistent nausea unresponsive to dose reduction is a red flag for contaminated synthesis.

Verify the supplier's 503B registration status. The FDA maintains a public database of registered outsourcing facilities. If your vendor isn't listed, the peptide lacks regulatory oversight and likely wasn't synthesised under cGMP standards. Request an HPLC purity certificate for the specific batch you purchased. Peptides synthesised before enforcement remain usable if stored correctly, but future orders should come from verified sources. The enforcement targeted sellers, not end-users. Possession isn't prosecuted, but distribution is.